The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.38
Bid: 1.36
Ask: 1.38
Change: 0.015 (1.10%)
Spread: 0.02 (1.471%)
Open: 1.36
High: 1.38
Low: 1.35
Prev. Close: 1.365
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

1 Nov 2023 10:51

Edison Investment Research Limited Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets 01-Nov-2023 / 10:51 GMT/BST The issuer is solely responsible for the content of this announcement.


 

London, UK, 1 November 2023

 

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO’s shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix’s shareholders would receive new RTWBIO shares at an implied c 46% premium to the level before Arix announced a strategic review. Meanwhile, RTWBIO’s management team anticipates that the deal would be single-digit accretive to the company’s NAV per share at completion.

During 2022 and so far in 2023, RTWBIO has made nine new investments and had seven successful IPOs or exits of portfolio companies. The acquisition would bring c $128m of Arix’s liquid assets, of which c $60m is expected to be in cash following completion of the scheme and the cost of the deal. RTWBIO intends to invest this capital in both public and private assets and can deploy cash quickly via investment in its ‘other public’ portfolio, which is made up of listed companies held by other RTW funds, to minimise cash drag. It can also deploy capital through its royalty and structured finance strategy, which provides an income stream with returns that are uncorrelated with equity returns and stock market volatility.Click here to view the full report.All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first company in-market 17 years ago, Edison has more than 100 employees and covers every economic sector. Headquartered in London, Edison also has offices in New York, Sydney and Wellington.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1762757 01-Nov-2023 

corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
20th Apr 20207:00 amRNSDirector/PDMR Shareholding
17th Apr 20207:00 amRNSQuarterly Update
15th Apr 20206:22 pmRNSNet Asset Value(s)
9th Apr 20204:22 pmRNSNotice of Annual Report
1st Apr 20206:00 pmRNSSeries B2 Financing in iTeos Therapeutics
1st Apr 20204:00 pmRNSName Change of Administrator and Company Secretary
18th Mar 202012:23 pmRNSDirector/PDMR Shareholding
18th Mar 202011:56 amRNSDirector/PDMR Shareholding
13th Mar 20207:00 amRNSNet Asset Value(s)
2nd Mar 20207:00 amRNSTotal Voting Rights
26th Feb 20207:00 amRNSIssue of Equity
19th Feb 20207:00 amRNSIssue of Equity
17th Feb 20205:10 pmRNSAnnouncement of Share Issuance
14th Feb 20207:00 amRNSNet Asset Value(s)
3rd Feb 20207:00 amRNSTotal Voting Rights
29th Jan 20207:00 amRNSIssue of Equity
27th Jan 20207:00 amRNSIssue of Equity
17th Jan 20204:30 pmRNSIssue of Equity
16th Jan 20207:00 amRNSIssue of Equity
15th Jan 20207:00 amRNSNet Asset Value(s)
23rd Dec 201911:28 amRNSHolding(s) in Company
16th Dec 20195:57 pmRNSNet Asset Value(s)
21st Nov 20193:45 pmRNSRTW leads $100M Financing in Avidity Biosciences
5th Nov 201910:00 amRNSHolding(s) in Company
5th Nov 20199:44 amRNSHolding(s) in Company
1st Nov 20197:00 amRNSTotal Voting Rights
30th Oct 20193:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.